Full text is available at the source.
Abstract
Diabetes mellitus type 2 is the primary driver of chronic kidney disease.
- Renin-angiotensin-aldosterone system inhibitors are foundational treatments for chronic kidney disease in type 2 diabetes.
- Recent studies suggest sodium glucose cotransporter 2 inhibitors may provide renal benefits.
- Glucagon-like peptide-1 receptor agonists are also associated with renal health improvements.
- The effects of combining sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists are not well understood.
Simplified